体外受精过程中可追溯性综合方案:多中心失效模式与效应分析的结果
该多中心失效模式与效应分析(FMEA)在7个意大利中心开展,历时21个月,识别了体外受精可追溯性流程中的潜在失效模式并实施纠正措施,结果显示所有中心的风险优先数(RPN)均显著降低至<15,并据此设计了一套简单全面的可追溯性系统。
要点
- 各中心平均识别19.3个流程步骤和41.9个潜在失效模式。
- 实施纠正措施后,所有中心所有步骤的RPN均<15。
- 每个体外受精中心都应有明确可靠的患者身份和细胞可追溯性方案。
核心结论
- 使用包含体外受精过程中最易感阶段的简单全面可追溯性系统可将错配风险降至最低。
研究设计与样本
- 多中心失效模式与效应分析(FMEA),选取7个意大利代表性中心(3个公立、4个私立),研究历时21个月(2015年4月至2016年12月),由专家团队集中协调。
- 每个中心组建多学科团队,按照国际联合委员会(Joint Commission International)方法进行FMEA分析。
主要发现
- 各中心平均识别19.3(标准差±5.8)个相关流程步骤和41.9(标准差±12.4)个潜在失效模式。
- 平均6.4个步骤(范围2-12,标准差±3.60)的风险优先数(RPN)≥15。
- 共集中分析293个失效模式,其中45个被认为处于中/高风险。
- 实施纠正措施并重新评估后,所有中心的RPN均显著降低(所有步骤RPN<15)。
关键数值与推荐
- 识别出七个主要流程阶段:卵母细胞采集、精子采集、配子处理、授精、胚胎培养、胚胎移植和配子/胚胎冷冻保存。
- 实施纠正措施后所有中心所有步骤的RPN均<15。
临床怎么用
- 每个体外受精中心都应有明确可靠的患者身份识别和操作过程中细胞可追溯性方案。
- 本研究结果可支持体外受精团队更好地识别其方案中的关键步骤、理解识别与见证过程,并通过引入经验证的纠正措施提升安全性。
局限性
- FMEA的有效性因判断的主观性而普遍受到质疑。
- 本研究设计通过引入外部专家分析FMEA结果降低了这一风险。
- 未考虑精子/卵母细胞捐赠、进出口和植入前遗传学检测等特定情况。
- 本研究仅局限于分析可能导致错配的失效模式,其他可能的操作错误未纳入。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Can traceability of gametes and embryos be ensured during IVF? SUMMARY ANSWER: The use of a simple and comprehensive traceability system that includes the most susceptible phases during the IVF process minimizes the risk of mismatches. WHAT IS KNOWN ALREADY: Mismatches in IVF are very rare but unfortunately possible with dramatic consequences for both patients and health care professionals. Traceability is thus a fundamental aspect of the treatment. A clear process of patient and cell identification involving witnessing protocols has to be in place in every unit. To identify potential failures in the traceability process and to develop strategies to mitigate the risk of mismatches, previously failure mode and effects analysis (FMEA) has been used effectively. The FMEA approach is however a subjective analysis, strictly related to specific protocols and thus the results are not always widely applicable. To reduce subjectivity and to obtain a widespread comprehensive protocol of traceability, a multicentre centrally coordinated FMEA was performed. STUDY DESIGN, SIZE, DURATION: Seven representative Italian centres (three public and four private) were selected. The study had a duration of 21 months (from April 2015 to December 2016) and was centrally coordinated by a team of experts: a risk analysis specialist, an expert embryologist and a specialist in human factor. Principal investigators of each centre were first instructed about proactive risk assessment and FMEA methodology. A multidisciplinary team to perform the FMEA analysis was then formed in each centre. After mapping the traceability process, each team identified the possible causes of mistakes in their protocol. A risk priority number (RPN) for each identified potential failure mode was calculated. The results of the FMEA analyses were centrally investigated and consistent corrective measures suggested. The teams performed new FMEA analyses after the recommended implementations. PARTICIPANTS/MATERIALS, SETTING, METHODS: In each centre, this study involved: the laboratory director, the Quality Control & Quality Assurance responsible, Embryologist(s), Gynaecologist(s), Nurse(s) and Administration. The FMEA analyses were performed according to the Joint Commission International. MAIN RESULTS AND THE ROLE OF CHANCE: The FMEA teams identified seven main process phases: oocyte collection, sperm collection, gamete processing, insemination, embryo culture, embryo transfer and gamete/embryo cryopreservation. A mean of 19.3 (SD ± 5.8) associated process steps and 41.9 (SD ± 12.4) possible failure modes were recognized per centre. A RPN ≥15 was calculated in a mean of 6.4 steps (range 2-12, SD ± 3.60). A total of 293 failure modes were centrally analysed 45 of which were considered at medium/high risk. After consistent corrective measures implementation and re-evaluation, a significant reduction in the RPNs in all centres (RPN <15 for all steps) was observed. A simple and comprehensive traceability system was designed as the result of the seven FMEA analyses. LIMITATIONS, REASONS FOR CAUTION: The validity of FMEA is in general questionable due to the subjectivity of the judgments. The design of this study has however minimized this risk by introducing external experts for the analysis of the FMEA results. Specific situations such as sperm/oocyte donation, import/export and pre-implantation genetic testing were not taken into consideration. Finally, this study is only limited to the analysis of failure modes that may lead to mismatches, other possible procedural mistakes are not accounted for. WIDER IMPLICATIONS OF THE FINDINGS: Every single IVF centre should have a clear and reliable protocol for identification of patients and traceability of cells during manipulation. The results of this study can support IVF groups in better recognizing critical steps in their protocols, understanding identification and witnessing process, and in turn enhancing safety by introducing validated corrective measures. STUDY FUNDING/COMPETING INTEREST(S): This study was designed by the Italian Society of Embryology Reproduction and Research (SIERR) and funded by the Italian National Transplant Centre (CNT) of the Italian National Institute of Health (ISS). The authors have no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.
引用
- Rienzi L, Bariani F, Dalla Zorza M, et al. Comprehensive protocol of traceability during IVF: the result of a multicentre failure mode and effect analysis. Hum Reprod. 2017. PMID: 28575413. doi:10.1093/humrep/dex144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。